Business

Corona Vaccination: Bharat Biotech, which makes vaccine, claims its vaccine trial was successful for 2-year-old children, approval has already been received for 15 to 18 years

Written by admin

Corona Vaccination: Bharat Biotech, which makes vaccine, claims its vaccine trial was successful for 2-year-old children, approval has already been received for 15 to 18 years

The campaign to vaccinate children of 15 to 18 years of age in the country is going to start from January 3.

To overcome Kovid-19 infection, Bharat Biotech, a company that makes a vaccine named Covaxin, has claimed that its vaccine trial has been successful even on children between the ages of two to 14 years. If this claim of the company is approved by the government, then the way for vaccination of children between 2 to 14 years will be cleared in the country. The government has already given recognition to the vaccine for immunization of children aged 15 to 18 years and from January 3, the campaign to vaccinate these children is also going to start.

Study finds vaccine safe for children – Bharat Biotech

Krishna Ella, CMD, Bharat Biotech, has claimed that “the clinical data for covaccine in children is very encouraging. Vaccine safety is important for children. We are pleased to report that trial data from Covaccine has now proven that this vaccine is safe and effective for use in children. In this way we have achieved our goal of developing a safe and effective COVID-19 vaccine for adults as well as children.” Bharat Biotech has completed Phase II and III studies to determine the safety, reactogenicity and immunogenicity of Covaxin in healthy children and adolescents aged 2 to 18 years.

Covid 19 Vaccination: Precaution dose of corona vaccine will be imposed in the country from January 10, see here the complete details of the guidelines related to it

‘Not aware of any serious reaction’

The company has claimed in its statement that no serious reaction to Covaccine has been reported in its study. A total of 374 volunteers reported symptoms of either mild or moderate severity, of which 78.6 percent were cured within a day. However, complaints of pain are being received at the injection site.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

#Corona #Vaccination #Bharat #Biotech #vaccine #claims #vaccine #trial #successful #2yearold #children #approval #received #years

About the author

admin

Leave a Comment